A field where the unmet need significantly outweighs current medical solutions is debilitating neurodegenerative diseases of the central nervous system, including Multiple Sclerosis, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease. We actively seek partners who share our commitment to addressing these diseases and shaping a different future for those living with them. We are committed to slowing down or halting neurodegeneration, modulating neuroinflammation and facilitating neuroprotection, repair and remyelination. 

Multiple Sclerosis

Genetically Defined Neurological Diseases

Neurodegeneration

Translational Neuroscience and Technologies

Your dedicated partnering leads in Neuroscience

Brian Bronk

Head of BD&L MS/Neurology, Rare Blood Disorders, Rare Diseases & Innovative Technologies

Guy Griebel

External Innovation Rare and Neuroscience

Tarik Elgoutni

Senior Director BD Rare, Rare Blood and Neuroscience

Success Stories

Building upon our original partnership, the acquisition of Principia provides the opportunity to expand the development of the oral BTK inhibitor Tolebrutinib, which has successfully completed Phase 2 for the treatment of multiple sclerosis to other central nervous system diseases.

Denali Therapeutics and Sanofi are collaborating to develop RIPK1 Inhibitors for the treatment of neurological and inflammatory diseases. Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseases.